<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Spontaneous preterm birth: Overview of interventions for risk reduction
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Spontaneous preterm birth: Overview of interventions for risk reduction
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Spontaneous preterm birth: Overview of interventions for risk reduction
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julian N Robinson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Errol R Norwitz, MD, PhD, MBA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2176608473">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many risk factors for preterm birth (PTB) (
         <a class="graphic graphic_table graphicRef140776" href="/z/d/graphic/140776.html" rel="external">
          table 1
         </a>
         ) and many pathways leading from these risk factors to the terminal cascade of events resulting in preterm labor. Normal uterine quiescence becomes disrupted when local uterine factors stimulate the parturition cascade prematurely and/or suppressive factors that inhibit the cascade are withdrawn prematurely.
        </p>
        <p>
         Ideally, identification of risk factors for PTB both before conception and early in pregnancy will lead to interventions that help prevent this complication. However, few interventions have been proven to prolong pregnancy in individuals at risk. This goal has been elusive for several reasons: two-thirds of spontaneous PTB (sPTB) occur among individuals with no risk factors, causality has been difficult to prove (eg, a cofactor may be required, thus complicating the chain of causality), and no adequate animal model exists for the study of sPTB in humans.
        </p>
        <p>
         An overview of potential interventions to mitigate the risk for sPTB, when possible, will be reviewed here. Pathogenesis and an overview of risk factors for sPTB, diagnosis and treatment of preterm labor, and long-term maternal prognosis after a PTB are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">
          "Spontaneous preterm birth: Overview of risk factors and prognosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6785.html" rel="external">
          "Spontaneous preterm birth: Pathogenesis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6798.html" rel="external">
          "Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">
          "Inhibition of acute preterm labor"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3003609107">
         <span class="h1">
          POTENTIALLY EFFECTIVE INTERVENTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Application of one or more of the following interventions may reduce the risk of PTB. For some patients, the risk factor for PTB is clear and may be mitigated by a specific intervention. For other patients, the factors may be less clear but still may be mitigated by a multifactorial approach involving prenatal and self-care.
        </p>
        <p class="headingAnchor" id="H3658708259">
         <span class="h2">
          Optimize status of maternal medical disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Identification and optimization of chronic medical disorders before and during pregnancy can improve overall maternal health and, in turn, pregnancy outcome. (See
         <a class="medical medical_review" href="/z/d/html/448.html" rel="external">
          "The preconception office visit"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2358003629">
         <span class="h2">
          Prescribe aspirin for patients at high risk of preeclampsia
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients at high risk of developing preeclampsia, a daily dose of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (typically 81 to 162 mg orally) starting at 12 to 16 weeks of gestation can reduce the chances of developing preeclampsia and need for indicated PTB. High-risk factors include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous pregnancy with preeclampsia, especially early onset and with an adverse outcome.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type 1 or 2 diabetes mellitus.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic hypertension.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multifetal gestation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune disease with potential vascular complications (antiphospholipid syndrome, systemic lupus erythematosus).
        </p>
        <p>
        </p>
        <p>
         These data are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">
          "Preeclampsia: Prevention", section on 'Low-dose aspirin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3637425299">
         <span class="h2">
          Identify unhealthy behaviors and help patients achieve healthy behaviors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cigarette smoking and misuse of alcohol and prescription and nonprescription drugs are unhealthy behaviors that increase the risk for PTB. The following interventions may reduce the risk of PTB and all promote personal health regardless of future pregnancy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tobacco use
         </strong>
         – Identification of individuals who smoke tobacco products, education on the maternal and fetal risks associated with smoking, and help with smoking cessation are important to promote general health. It is likely that individuals who reduce or stop smoking will also reduce their risk for PTB, but this has not been proven. These data are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">
          "Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate", section on 'Preterm birth'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/115306.html" rel="external">
          "Tobacco and nicotine use in pregnancy: Cessation strategies and treatment options"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since 2010, in the United States, Medicaid programs are required to cover tobacco-cessation counseling and drug therapy for pregnant people without cost sharing, which might increase utilization of these services [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Substance use
         </strong>
         – Health care providers should ask about maternal substance use (eg, alcohol, misuse of prescription or nonprescription drugs), provide information on the maternal and fetal risks associated with the substance used, and help patients stop using the substance. Medication (
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         ) is recommended for those with an opioid use disorder. It is likely that this will reduce their risk for PTB, but this has not been proven. These data are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">
          "Substance use during pregnancy: Screening and prenatal care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4790.html" rel="external">
          "Opioid use disorder: Overview of treatment during pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87238.html" rel="external">
          "Opioid use disorder: Pharmacotherapy with methadone and buprenorphine during pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4798.html" rel="external">
          "Alcohol intake and pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2282299856">
         <span class="h2">
          Identify an abnormal BMI and encourage prepregnancy weight loss or gain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnant individuals with adequate nutrition and a normal body mass index (BMI) have better pregnancy outcomes than individuals who do not, which suggests that dietary interventions may have a role in preventing PTB in selected populations. Regardless of its effect on pregnancy, weight loss before pregnancy should be recommended for individuals with obesity because of the general health benefits. (See
         <a class="medical medical_review" href="/z/d/html/5370.html" rel="external">
          "Overweight and obesity in adults: Health consequences"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Evidence suggests that weight loss before pregnancy in individuals with obesity and appropriate weight gain during pregnancy can reduce the risk for PTB, but the data are not definitive. In a meta-analysis of randomized trials of the effects of dietary and lifestyle interventions in pregnancy on maternal weight and obstetric outcomes, the reduction in PTB was not statistically significant (relative risk [RR] 0.78, 95% CI 0.60-1.02, 13 trials, 2652 participants) [
         <a href="#rid2">
          2
         </a>
         ]. However, these trials had significant heterogeneity and were of low quality. (See
         <a class="medical medical_review" href="/z/d/html/433.html" rel="external">
          "Obesity in pregnancy: Complications and maternal management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/441.html" rel="external">
          "Gestational weight gain"
         </a>
         .)
        </p>
        <p>
         Patients with eating disorders can benefit from interventions to achieve a normal weight. Management of eating disorders and outcome are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4852.html" rel="external">
          "Eating disorders in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3469916101">
         <span class="h2">
          Discuss optimal pregnancy spacing and avoiding unplanned pregnancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals planning pregnancy are advised to space pregnancies at least 18 months apart. Short interpregnancy intervals (&lt;6 months) are associated with an increased risk of PTB and other adverse pregnancy outcomes (
         <a class="graphic graphic_table graphicRef89410" href="/z/d/graphic/89410.html" rel="external">
          table 2
         </a>
         ). However, the interval between pregnancies should not be excessive. A meta-analysis calculated that an interval ≥60 months also increased the risk for PTB (odds ratio [OR] 1.20, 95% CI 1.17-1.24) [
         <a href="#rid3">
          3
         </a>
         ]. The data behind these recommendations are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6767.html" rel="external">
          "Interpregnancy interval: Optimizing time between pregnancies"
         </a>
         .)
        </p>
        <p>
         Approximately 50 percent of pregnancies in the United States are unplanned. Providing contraception to prevent unintended pregnancies may reduce PTB as such pregnancies are associated with a higher risk of PTB [
         <a href="#rid4">
          4
         </a>
         ]. Providing postpartum contraception before the first postpartum visit can be helpful. In a large cohort study that examined the impact of postpartum contraceptive coverage within 18 months of birth, the odds of PTB decreased by 1.1 percent for every month of contraceptive coverage [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">
          "Contraception: Counseling and selection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">
          "Contraception: Postpartum counseling and methods"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3755601348">
         <span class="h2">
          Reduce the iatrogenic occurrence of multifetal gestations
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients undergoing assisted reproduction, strategies should be utilized to reduce the likelihood of a multiple gestation and particularly a high order multiple gestation (triplets and above). These strategies include single embryo transfer in patients undergoing in vitro fertilization (IVF). In patients undergoing ovulation induction without IVF, strategies include use of either
         <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">
          clomiphene
         </a>
         citrate or aromatase inhibitors, as appropriate, rather than gonadotropins. In patients with an excessive number of mature follicles, conversion to IVF or cycle cancellation should be considered. If a high order multiple gestation occurs, multifetal pregnancy reduction can improve neonatal outcome. (See
         <a class="medical medical_review" href="/z/d/html/7417.html" rel="external">
          "Strategies to control the rate of high order multiple gestation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6743.html" rel="external">
          "Multifetal pregnancy reduction and selective termination"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2125341692">
         <span class="h2">
          Consider effects of cervical/uterine surgery on future pregnancies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients undergoing pregnancy termination, procedural termination may be associated with higher rates of subsequent PTB than medication abortion. Appropriate use of cervical ripening agents may reduce the risk of cervical injury before procedural evacuation. For patients undergoing miscarriage, avoiding surgical evacuation of uterine contents (if safely possible) by expectant management or medical induction may reduce PTB risk in subsequent pregnancies. These interventions are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">
          "Overview of pregnancy termination"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130834.html" rel="external">
          "Pregnancy loss (miscarriage): Counseling and comparison of treatment options and discussion of related care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with some types of fibroids (eg, submucosal) and a history of pregnancy loss or previable PTB, myomectomy before pregnancy may improve pregnancy outcome. Decision-making is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6801.html" rel="external">
          "Uterine fibroids (leiomyomas): Issues in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5444.html" rel="external">
          "Recurrent pregnancy loss: Management", section on 'Uterine abnormalities'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients undergoing treatment of cervical intraepithelial neoplasia should undergo the procedure that best diagnoses or prevents cervical cancer and also incurs the lowest risk of reproductive effects. Serial cervical length measurements should be performed in subsequent pregnancies before making a diagnosis of cervical insufficiency or providing prophylactic treatment (see following bullet on monitoring cervical length). (See
         <a class="medical medical_review" href="/z/d/html/3210.html" rel="external">
          "Reproductive effects of cervical excisional and ablative procedures"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/450.html" rel="external">
          "Short cervix before 24 weeks: Screening and management in singleton pregnancies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H676383946">
         <span class="h2">
          Monitor cervical length; treat patients with a short cervix or cervical insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients at high risk of cervical insufficiency should undergo cervical length measurement at approximately 16 weeks of gestation and serially thereafter (every 1 to 2 weeks through 24 weeks) (
         <a class="graphic graphic_algorithm graphicRef107318" href="/z/d/graphic/107318.html" rel="external">
          algorithm 1
         </a>
         ). Some authorities, including the Society for Maternal-Fetal Medicine, consider routine midtrimester cervical length measurement at the fetal anatomy scan reasonable regardless of risk of PTB [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/450.html" rel="external">
          "Short cervix before 24 weeks: Screening and management in singleton pregnancies"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progesterone supplementation
         </strong>
         – For patients with singleton pregnancies and no history of prior PTB who have a short cervix (≤25 mm) on transvaginal ultrasound examination at 18 to 24 weeks, we prescribe daily vaginal progesterone to reduce the risk for PTB. Progesterone supplementation appears to reduce the risk of PTB by approximately 20 percent in these individuals. A review of evidence is available separately. (See
         <a class="medical medical_review" href="/z/d/html/16560.html" rel="external">
          "Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth", section on 'Singleton pregnancy with a short cervix'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with singleton pregnancies and a positive history of prior PTB, we would offer vaginal progesterone to those with a short cervix (≤25 mm) on transvaginal ultrasound examination at 16 to 24 weeks. Cerclage is another option. (See
         <a class="medical medical_review" href="/z/d/html/16560.html" rel="external">
          "Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth", section on 'Singleton pregnancy with prior preterm birth'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cerclage
         </strong>
         – We often suggest cerclage for:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with two or more second-trimester pregnancy losses/PTBs associated with painless cervical dilation (history-indicated cerclage). (See
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency", section on 'Obstetric history-based diagnosis of cervical insufficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency", section on 'Obstetric history-based cervical insufficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a history of sPTB in whom the diagnosis of cervical insufficiency is uncertain, but a short cervical length (≤25 mm) is detected on transvaginal ultrasound examination at 18 to 24 weeks (ultrasound-indicated cerclage). (See
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency", section on 'Ultrasound-based diagnosis of cervical insufficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency", section on 'Ultrasound-based cervical insufficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with physical examination-based cervical insufficiency before 24 weeks of gestation. (See
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency", section on 'Physical examination-based diagnosis of cervical insufficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency", section on 'Physical examination-based cervical insufficiency'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with a very short cervical length (&lt;10 or 15 mm) measured on transvaginal ultrasound examination at 16 to 24 weeks. (See
         <a class="medical medical_review" href="/z/d/html/450.html" rel="external">
          "Short cervix before 24 weeks: Screening and management in singleton pregnancies", section on 'Patients with NO prior spontaneous preterm birth'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2805569637">
         <span class="h2">
          Reduce maternal infection risk
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Perform a routine first-trimester urine culture and treat asymptomatic bacteriuria
         </strong>
         – A first-trimester urine culture is routine in all pregnancies [
         <a href="#rid7">
          7,8
         </a>
         ]. In addition, serial prenatal urine culture screening is recommended for patients at high risk for asymptomatic bacteriuria (eg, individuals with sickle cell trait, recurrent urinary tract infections, diabetes mellitus, underlying kidney disease). Reliance on symptoms to prompt screening is inadequate because symptoms such as frequency and nocturia are often attributed to the pregnant state. (See
         <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">
          "Urinary tract infections and asymptomatic bacteriuria in pregnancy", section on 'Asymptomatic bacteriuria'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pregnant persons with asymptomatic bacteriuria should be treated with antibiotics to reduce their risk of developing pyelonephritis and possibly reduce the risk of PTB. In a meta-analysis (14 randomized trials), treatment of asymptomatic bacteriuria clearly and substantially decreased the frequency of asymptomatic bacteriuria (RR 0.25, 95% CI 0.14-0.48), pyelonephritis (RR 0.23, 95% CI 0.13-0.41) [
         <a href="#rid9">
          9
         </a>
         ], and low birth weight (RR 0.66, 95% CI 0.49-0.89), but a difference in PTB was not established.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduce the risk of acquiring malaria in endemic areas
         </strong>
         – Prevention of malaria infection by mosquito avoidance and prophylactic drug therapy, and treatment of established malaria infection, can reduce the risk for PTB. Issues related to malaria in pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4812.html" rel="external">
          "Malaria in pregnancy: Prevention and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3770951464">
         <span class="h2">
          Surgically correct some congenital uterine abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical correction of a uterine septum, bicornuate uterus, or communicating hemiuterus may reduce the risk for recurrent miscarriage or very early PTB or miscarriage. Selection of candidates, procedures, and prognosis are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3292.html" rel="external">
          "Congenital uterine anomalies: Surgical repair"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3409169989">
         <span class="h2">
          Tocolytic treatment of acute preterm labor
         </span>
         <span class="headingEndMark">
          —
         </span>
         We prescribe tocolytic therapy as part of the management of acute preterm labor. Short-term tocolysis is endorsed by most guidelines since delaying delivery for 48 hours enables maternal administration of glucocorticoids to achieve the maximum fetal effect [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery"
         </a>
         .)
        </p>
        <p>
         Tocolytic therapy of an acute episode of idiopathic preterm labor often abolishes contractions temporarily but does not remove the underlying stimulus that initiated the process of parturition (eg, infection, inflammation, uterine overdistention, decidual hemorrhage, cervical insufficiency) or reverse parturitional changes in the uterus. The net effect is that tocolytics may delay delivery by a few days, but do not consistently prolong pregnancy by weeks or months. These data are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">
          "Inhibition of acute preterm labor"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2133585687">
         <span class="h1">
          INEFFECTIVE AND UNPROVEN INTERVENTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2939630342">
         <span class="h2">
          Progesterone supplementation for patients with a prior preterm birth
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neither
         <a class="drug drug_general" data-topicid="16452" href="/z/d/drug information/16452.html" rel="external">
          hydroxyprogesterone caproate
         </a>
         (Makena) nor vaginal progesterone reduces the risk of recurrent PTB in this population. These patients should be followed sonographically to identify those with a short cervix at 16 to 24 weeks. Vaginal progesterone appears to be useful in patients with a short cervix; cerclage is another option. (See
         <a class="medical medical_review" href="/z/d/html/16560.html" rel="external">
          "Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth", section on 'Singleton pregnancy with a short cervix'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16560.html" rel="external">
          "Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth", section on 'Singleton pregnancy with prior preterm birth'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency", section on 'Ultrasound-based cervical insufficiency'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3064047659">
         <span class="h2">
          Monitoring uterine contraction frequency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although an increase in uterine activity is a prerequisite for labor, randomized trials and a meta-analysis have shown that measuring the frequency of uterine contractions by self-palpation/detection of signs of labor or through use of a home uterine activity monitor appears to increase the use of tocolytics without
         <strong>
         </strong>
         leading to a clear clinically meaningful reduction in the rate of PTB [
         <a href="#rid11">
          11,12
         </a>
         ]. Moreover, such an approach increases the frequency of unscheduled antenatal visits. The American College of Obstetricians and Gynecologists (ACOG) recommends not using home uterine activity monitoring as a strategy for prediction or prevention of PTB [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1324002365">
         <span class="h2">
          Prophylactic tocolytics
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not prescribe prophylactic tocolytic medication. Prophylactic tocolytic therapy for prevention of PTB in high-risk asymptomatic pregnant people was not effective in randomized trials, although few such trials have been conducted [
         <a href="#rid14">
          14,15
         </a>
         ]. Maintenance tocolysis, which has been studied more extensively, was also ineffective in randomized trials. These data are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6795.html" rel="external">
          "Management of pregnancy after resolution of an episode of acute idiopathic preterm labor"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4129332195">
         <span class="h2">
          Low-dose aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not prescribe low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for prevention of PTB in patients at low risk of developing preeclampsia. We agree with ACOG's guidelines (published before the ASPIRIN and APRIL trials [described below]), which state that low-dose aspirin should not be used in an attempt to prevent sPTB but should be considered for patients with risk factors for preeclampsia to prevent this disorder and its consequences, including indicated PTB [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Although the putative beneficial effects of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         on PTB is most likely explained by the prevention of indicated PTB due to preeclampsia, an independent effect on sPTB is plausible and should be studied further. It has been hypothesized that low-dose aspirin may reduce the risk of sPTB by inhibiting the inflammatory and uteroplacental ischemia pathways leading to this outcome (
         <a class="graphic graphic_figure graphicRef59393" href="/z/d/graphic/59393.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          ASPIRIN
         </a>
         trial evaluated the use of low-dose aspirin for prevention of PTB as the primary outcome [
         <a href="#rid17">
          17
         </a>
         ]. Nearly 12,000 nulliparous individuals with singleton pregnancies in six low- and middle-income countries were randomly assigned to receive 81 mg aspirin or placebo beginning at 6+0 to 13+6 weeks of gestation and continuing until 36+6 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         reduced PTB &lt;37 weeks (11.6 versus 13.1 percent, relative risk [RR] 0.89, 95% CI 0.81-0.98) and &lt;34 weeks (3.3 versus 4.0 percent, RR 0.75, 95% CI 0.61-0.93) and also reduced fetal loss and perinatal mortality; other maternal or neonatal outcomes were similar between groups. These benefits occurred in part because of a 60 percent reduction in participants who gave birth before 34 weeks with a hypertensive disorder of pregnancy (0.1 versus 0.4 percent); the incidence of hypertensive disorders in late pregnancy was not reduced.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Limitations of the trial included lack of data on the effect of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         in participants who were multiparous, carrying a multiple gestation, living in a high-income country, or residing in an area where low-dose aspirin is routinely recommended for patients at moderate or high risk for developing preeclampsia. The trial also did not distinguish between sPTB and indicated PTB.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The APRIL trial was the first trial to evaluate
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (80 mg) versus placebo in patients (n = 387) with singleton pregnancies plus a history of sPTB [
         <a href="#rid18">
          18
         </a>
         ]. The intervention was initiated between 8 and 16 weeks of gestation and continued until 36 weeks or delivery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         prophylaxis did not result in a statistically significant reduction in total PTB &lt;37 weeks (21.2 versus 25.4 percent in the placebo group; RR 0.83, 95% CI 0.58-1.20), including in patients with ≥80 percent medication adherence (19.2 versus 24.8 percent; RR 0.77, 95% CI 0.48-1.25). The two subgroups of spontaneous and indicated PTB &lt;37 weeks of gestation also did not significantly differ between participants allocated to aspirin versus placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A major limitation of the trial was that the PTB rate in both groups was less than anticipated, possibly because nearly two-thirds of participants were prescribed progesterone supplementation and approximately 10 percent underwent cervical cerclage. The findings suggest that a trial would need to be 10-fold larger than APRIL to determine whether
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         can prevent recurrent PTB [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Trials evaluating the use of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for prevention of preeclampsia in high-risk patients are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">
          "Preeclampsia: Prevention", section on 'Low-dose aspirin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4188921887">
         <span class="h2">
          Pessary
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not prescribe pessaries for patients with a short cervix as the body of evidence does not support using a pessary to prolong gestation or improve neonatal outcome. This evidence is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency", section on 'Pessary'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H178628697">
         <span class="h2">
          Bed rest
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bed rest improves uteroplacental blood flow and can lead to a slight increase in birth weight, but there is no evidence that it decreases the incidence of PTB [
         <a href="#rid20">
          20-22
         </a>
         ], even in patients with a short cervix [
         <a href="#rid23">
          23,24
         </a>
         ]. Although underpowered, the only randomized trial attempting to determine whether hospitalization of patients with arrested preterm labor improved outcome found hospitalized patients had a similar rate of PTB as those who were discharged home and thus presumably more active [
         <a href="#rid25">
          25
         </a>
         ]. In patients with a short cervix, observational studies have reported a paradoxical higher rate of PTB in those with reduced physical activity [
         <a href="#rid23">
          23,26
         </a>
         ].
        </p>
        <p>
         Bed rest also has potential harms: it increases the risk of thromboembolic events, has negative psychosocial effects, and leads to physical deconditioning [
         <a href="#rid27">
          27-30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3910632921">
         <span class="h2">
          Avoiding sexual intercourse
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no evidence of harm from sexual activity during pregnancy, therefore abstinence has no role in strategies to prevent PTB [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2913340462">
         <span class="h2">
          Routinely screening for cervicovaginal and sexually transmitted infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         We screen for chlamydia, gonorrhea, and syphilis according to
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Ftreatment-guidelines%2Fdefault.htm&amp;token=GG%2FgjfxydbWPRfxXxvkuO3Z7rCvPfYCbHpI0XhRbEzgb1PiLFQLuos1hzlgAVwGZBa1nyF6yQEYtZyuOXda5Pg%3D%3D&amp;TOPIC_ID=140781" target="_blank">
          US Centers for Disease Control and Prevention guidelines
         </a>
         . The purpose is to prevent maternal disease and transmission. (See
         <a class="medical medical_review" href="/z/d/html/446.html" rel="external">
          "Prenatal care: Initial assessment", section on 'Standard panel'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/446.html" rel="external">
          "Prenatal care: Initial assessment", section on 'Selective screening'
         </a>
         .)
        </p>
        <p>
         Some trials have reported a reduction in PTB with routine screening and treatment for asymptomatic vaginal infection in the early second trimester [
         <a href="#rid33">
          33
         </a>
         ], while others have reported no benefit [
         <a href="#rid34">
          34,35
         </a>
         ]. Discordant findings may be due to confounding by recolonization or reinfection after therapy, intercurrent use of nonprotocol antibiotics, and failure to culture fastidious bacteria (eg,
         <em>
          Mycoplasma hominis, Ureaplasma urealyticum
         </em>
         ), leading to misclassifications of individuals as noninfected.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chlamydia, gonorrhea, syphilis
         </strong>
         – There is no evidence that treatment of chlamydia, gonorrhea, or syphilis prolongs gestation. The only controlled trial that evaluated the effect of treatment of chlamydia on gestational duration did not show a reduction in PTB [
         <a href="#rid36">
          36
         </a>
         ]. However, screening for and treatment of these infections is recommended to prevent other maternal and neonatal sequelae. (See
         <a class="medical medical_review" href="/z/d/html/15893.html" rel="external">
          "Clinical manifestations and diagnosis of
          <i>
           Neisseria gonorrhoeae
          </i>
          infection in adults and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15892.html" rel="external">
          "Treatment of uncomplicated gonorrhea (
          <i>
           Neisseria gonorrhoeae
          </i>
          infection) in adults and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4794.html" rel="external">
          "Syphilis in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7579.html" rel="external">
          "Treatment of
          <i>
           Chlamydia trachomatis
          </i>
          infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bacterial vaginosis (BV),
         </strong>
         <strong>
          <em>
           Ureaplasma
          </em>
         </strong>
         <strong>
          , group B
         </strong>
         <strong>
          <em>
           Streptococcus
          </em>
         </strong>
         <strong>
          (GBS)
         </strong>
         – Prospective controlled studies and meta-analyses have reported either a modest or no effect of antibiotic treatment on prolonging gestation in asymptomatic patients who screened positive for BV [
         <a href="#rid35">
          35,37-40
         </a>
         ],
         <em>
          Ureaplasma urealyticum
         </em>
         [
         <a href="#rid41">
          41,42
         </a>
         ], or GBS [
         <a href="#rid43">
          43
         </a>
         ], although these studies are likely confounded by recolonization or reinfection after therapy and intercurrent use of nonprotocol antibiotics. GBS screening in late pregnancy and chemoprophylaxis for prevention of early-onset neonatal GBS infection is recommended. (See
         <a class="medical medical_review" href="/z/d/html/438.html" rel="external">
          "Prevention of early-onset group B streptococcal disease in neonates"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with BV and a previous PTB may benefit from BV screening and treatment, but there are insufficient data to recommend this as a routine practice. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/113103.html" rel="external">
          "Bacterial vaginosis: Initial treatment", section on 'Asymptomatic pregnant persons'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Trichomonas
          </em>
         </strong>
         – Screening and treatment of asymptomatic
         <em>
          Trichomonas
         </em>
         infection in pregnant females who are not infected with HIV is not recommended because treatment did not reduce PTB in randomized trials [
         <a href="#rid34">
          34,44-46
         </a>
         ]. By contrast, screening and treatment are recommended for pregnant patients infected with HIV to reduce the risks for pelvic inflammatory disease. (See
         <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">
          "Trichomoniasis: Clinical manifestations and diagnosis", section on 'Diagnostic evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139046.html" rel="external">
          "Trichomoniasis: Treatment", section on 'Pregnant'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1329337662">
         <span class="h2">
          Empiric antibiotic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric antibiotic therapy in patients with intact membranes does not reduce PTB. A meta-analysis of 17 randomized trials evaluated use of prophylactic antibiotics for prevention of PTB based on abnormal vaginal flora (12 trials), a previous PTB (three trials), and a positive fetal fibronectin test result (two trials) [
         <a href="#rid47">
          47
         </a>
         ]. There was no significant association between antibiotic treatment and reduction in PTB regardless of the criteria used to assess risk, the antimicrobial drug administered, or gestational age at the time of treatment (overall combined random effect for delivery &lt;37 weeks RR 1.03, 95% CI 0.86-1.24).
        </p>
        <p>
         Another meta-analysis of randomized trials limited studies of antibiotic prophylaxis in the second or third trimester also found that the intervention did not significantly reduce the risk of PTB (RR 0.85, 95% CI 0.64-1.14, five trials, 1480 participants) or preterm prelabor rupture of membranes (RR 0.31, 95% CI 0.06-1.49, one trial, 229 participants); however, the included studies were of low methodologic quality [
         <a href="#rid48">
          48
         </a>
         ]. Subsequent randomized trials have also not shown a benefit [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1832329335">
         <span class="h2">
          Enhanced prenatal care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Enhanced prenatal care has not reduced the risk for PTB compared with routine prenatal care. These data are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/446.html" rel="external">
          "Prenatal care: Initial assessment", section on 'Effectiveness'
         </a>
         .)
        </p>
        <p>
         Nevertheless, implementation of case management programs or specialty clinics for PTB prevention continue to be advocated and can facilitate implementation of the potentially effective interventions described above, provide social and emotional support to reduce stress (eg, assign a race- and language-matched Doula, refer for mental health services), and address socioeconomic factors associated with a high risk of PTB [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4217059796">
         <span class="h2">
          Treatment of periodontal disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although treatment of periodontal disease contributes to overall oral health, there is no strong evidence that treatment of periodontal disease improves pregnancy outcome. A 2023 meta-analysis (12 randomized trials, over 5700 pregnant participants) found that periodontal treatment (scaling and root planing) had no significant benefit in reducing PTB and low birth weight except when combined with
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         mouthwash [
         <a href="#rid51">
          51
         </a>
         ]. There were many limitations to the trials, such as concerns about survival bias, lack of information about adherence with chlorhexidine mouthwash, and inability to assess for potential effect modification by factors such as oral health status at baseline. A large well-designed randomized trial is needed to determine the effect of periodontal treatment with/without oral antimicrobial rinsing on obstetric outcomes.
        </p>
        <p>
         Several hypotheses have been proposed to explain why periodontal treatment does not clearly reduce the risk for adverse pregnancy outcomes. Possibilities include [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of causality. Periodontitis may not be a direct or indirect cause of PTB or low birth weight.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shared risk factors may mitigate the effect of treatment. Some risk factors for both periodontitis and poor pregnancy outcome (eg, smoking) are not affected by periodontal treatment. Furthermore, PTB is likely the end result of a variety of environmental, behavioral, social, biological, and possibly genetic factors so periodontal treatment alone is unlikely to have a major impact on reducing risk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Underpowered trials. Very large trials would be required to detect significant reductions in very or extreme PTB rates since these are much less common than late PTBs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of a consistent definition of periodontal disease. This has led to inclusion of individuals with mild disease whose pregnancies may not benefit from treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of periodontal disease in the trials was inadequate to affect pregnancy outcome. To demonstrate a beneficial effect, treatment may have to start before pregnancy or very early in pregnancy, continue longer, or be more intense. If PTB is related to changes in the genital tract microbiome induced by changes in the oral microbiome, local treatment of oral inflammation may not reverse genital tract changes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1849987571">
         <span class="h2">
          Dietary modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         In systematic reviews, isocaloric protein supplements [
         <a href="#rid53">
          53
         </a>
         ], balanced protein/energy supplements [
         <a href="#rid54">
          54
         </a>
         ], and high protein supplements [
         <a href="#rid54">
          54
         </a>
         ] did not reduce the rate of PTB. Most studies show that vitamin supplements during pregnancy do not reduce the risk of PTB [
         <a href="#rid55">
          55-61
         </a>
         ], although they have other health benefits. There may be potential benefits of micronutrient supplementation in specific subpopulations of pregnant people, such as those who are undernourished or infected with HIV [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         In a 2018 meta-analysis of placebo-controlled randomized trials of omega-3 long-chain polyunsaturated fatty acids (n-3 PUFAs) supplements or dietary additions during pregnancy, n-3 PUFAs reduced PTB &lt;37 and &lt;34 weeks, with a corresponding trend for reduction in perinatal death [
         <a href="#rid63">
          63
         </a>
         ]. These and subsequent discordant data and recommendations regarding fish consumption and n-3 PUFA supplementation during pregnancy are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/431.html" rel="external">
          "Fish consumption and marine omega-3 fatty acid supplementation in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H881293345">
         <span class="h2">
          Retiring from the workforce
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with uncomplicated pregnancies who are employed where there are no greater potential hazards than those encountered in routine daily life may continue to work without interruption until the onset of labor. Nevertheless, the physical demands of the job should be considered, especially in individuals at high risk of PTB, and working hours and occupational physical activity during pregnancy should be limited using common sense and local guidelines [
         <a href="#rid64">
          64-67
         </a>
         ].
        </p>
        <p>
         The effects of reducing occupational fatigue on PTB rates have not been evaluated in randomized trials. Maternity legislation in many European countries has regulated work schedules and working conditions for pregnant people; however, none of the European countries except France has experienced a reduction in PTB rates [
         <a href="#rid68">
          68
         </a>
         ]. Nevertheless, paid maternity leave, guaranteed job protection, and regulation of hazardous working conditions remain desirable societal goals.
        </p>
        <p class="headingAnchor" id="H3799774023">
         <span class="h2">
          Social support and stress reduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although social support during pregnancy has resulted in improvements in short-term psychosocial outcome, it has not significantly reduced the rate of PTB. A systematic review concluded that social support was not sufficiently powerful to improve the obstetric outcome of the pregnancy in which it was provided, possibly because of the immense social deprivation experienced by most of the participants in the trials examined [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
         There are limited data on other interventions for reducing stress in pregnant people (eg, relaxation or mind-body therapies [eg, meditation, massage, yoga, breathing exercises, music therapy, aromatherapy]). Available trials are small and of poor quality; clear effects on birth outcomes have not been proven [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3091883423">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114351.html" rel="external">
          "Society guideline links: Preterm labor and birth"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H130907909">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15609.html" rel="external">
          "Patient education: Preterm labor (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/6726.html" rel="external">
          "Patient education: Preterm labor (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/8424.html" rel="external">
          "Patient education: Bacterial vaginosis (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/8407.html" rel="external">
          "Patient education: Management of a cervical biopsy with precancerous cells (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2679755073">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors for preterm birth (PTB)
         </strong>
         – There are many maternal and fetal risk factors for preterm birth (PTB) (
         <a class="graphic graphic_table graphicRef140776" href="/z/d/graphic/140776.html" rel="external">
          table 1
         </a>
         ). Some are reversible, others are not. Identification of risk factors for PTB before conception or early in pregnancy ideally leads to interventions that could help prevent this complication. (See
         <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">
          "Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to risk mitigation
         </strong>
         – For some patients, the risk factor for PTB is clear and may be mitigated by a specific intervention. For other patients, the factors may be less clear but still may be mitigated by a multifactorial approach involving prenatal and self-care. Potentially effective interventions are listed in the table (
         <a class="graphic graphic_table graphicRef140778" href="/z/d/graphic/140778.html" rel="external">
          table 3
         </a>
         ) and discussed in detail in separate topic reviews. They include the following (see
         <a class="local">
          'Potentially effective interventions'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Optimize management of any maternal medical disorders (see
         <a class="medical medical_review" href="/z/d/html/448.html" rel="external">
          "The preconception office visit"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prescribe low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for patients at high risk of developing preeclampsia (see
         <a class="medical medical_review" href="/z/d/html/6817.html" rel="external">
          "Preeclampsia: Prevention", section on 'Low-dose aspirin'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Provide counseling and intervention to reduce tobacco and substance use (see
         <a class="medical medical_review" href="/z/d/html/115306.html" rel="external">
          "Tobacco and nicotine use in pregnancy: Cessation strategies and treatment options"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4799.html" rel="external">
          "Substance use during pregnancy: Screening and prenatal care"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Identify individuals with abnormal body mass index (BMI) and encourage prepregnancy weight loss or gain (see
         <a class="medical medical_review" href="/z/d/html/433.html" rel="external">
          "Obesity in pregnancy: Complications and maternal management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/441.html" rel="external">
          "Gestational weight gain"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4852.html" rel="external">
          "Eating disorders in pregnancy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Provide counseling regarding optimal pregnancy spacing and avoiding unplanned pregnancies (see
         <a class="medical medical_review" href="/z/d/html/6767.html" rel="external">
          "Interpregnancy interval: Optimizing time between pregnancies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6708.html" rel="external">
          "Contraception: Postpartum counseling and methods"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduce iatrogenic multifetal gestations (see
         <a class="medical medical_review" href="/z/d/html/7417.html" rel="external">
          "Strategies to control the rate of high order multiple gestation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6743.html" rel="external">
          "Multifetal pregnancy reduction and selective termination"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Consider the impact of cervical/uterine surgery on future pregnancies (eg, prior surgical evacuation for pregnancy termination or miscarriage, myomectomy for fibroids, surgical treatment of cervical intraepithelial neoplasia) (see
         <a class="medical medical_review" href="/z/d/html/3313.html" rel="external">
          "Overview of pregnancy termination"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130834.html" rel="external">
          "Pregnancy loss (miscarriage): Counseling and comparison of treatment options and discussion of related care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6801.html" rel="external">
          "Uterine fibroids (leiomyomas): Issues in pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3210.html" rel="external">
          "Reproductive effects of cervical excisional and ablative procedures"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Monitor for short cervix (≤25 mm) and treat affected patients with vaginal progesterone or cerclage; identify cervical insufficiency and treat affected patients with cerclage (see
         <a class="medical medical_review" href="/z/d/html/16560.html" rel="external">
          "Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth", section on 'Singleton pregnancy with a short cervix'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">
          "Cervical insufficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/450.html" rel="external">
          "Short cervix before 24 weeks: Screening and management in singleton pregnancies"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Address maternal infection risk, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Routinely perform a first-trimester urine culture and treat asymptomatic bacteriuria (see
         <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">
          "Urinary tract infections and asymptomatic bacteriuria in pregnancy", section on 'Asymptomatic bacteriuria'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Reduce the risk of acquiring malaria in endemic areas (see
         <a class="medical medical_review" href="/z/d/html/4812.html" rel="external">
          "Malaria in pregnancy: Prevention and treatment"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Surgically correct congenital uterine abnormalities, when appropriate (see
         <a class="medical medical_review" href="/z/d/html/3292.html" rel="external">
          "Congenital uterine anomalies: Surgical repair"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treat acute preterm labor with tocolytics (see
         <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">
          "Inhibition of acute preterm labor"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ineffective and unproven interventions
         </strong>
         – Other interventions to mitigate the risk of spontaneous PTB (sPTB) have been proposed. However, based on the available evidence, these strategies are either ineffective or uncertain. In particular, we would not use the following interventions for prevention of sPTB:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Routine monitoring of uterine contraction frequency (see
         <a class="local">
          'Monitoring uterine contraction frequency'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prophylactic tocolytics (see
         <a class="local">
          'Prophylactic tocolytics'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Routine use of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         in the absence of a high-risk factor for preeclampsia (see
         <a class="local">
          'Low-dose aspirin'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bed rest (see
         <a class="local">
          'Bed rest'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prophylactic empiric antibiotic therapy (see
         <a class="local">
          'Empiric antibiotic therapy'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Progesterone supplementation for patients with a history of PTB but without a short cervix (See
         <a class="medical medical_review" href="/z/d/html/16560.html" rel="external">
          "Progesterone supplementation to reduce the risk of spontaneous preterm labor and birth", section on 'Singleton pregnancy with prior preterm birth'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other unproven strategies are discussed above. (See
         <a class="local">
          'Ineffective and unproven interventions'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          http://www.cdc.gov/mmwr/volumes/65/wr/mm6532a4.htm?s_cid=mm6532a4_e.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thangaratinam S, Rogozinska E, Jolly K, et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ 2012; 344:e2088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conde-Agudelo A, Rosas-Bermúdez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA 2006; 295:1809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orr ST, Miller CA, James SA, Babones S. Unintended pregnancy and preterm birth. Paediatr Perinat Epidemiol 2000; 14:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez MI, Chang R, Thiel de Bocanegra H. The impact of postpartum contraception on reducing preterm birth: findings from California. Am J Obstet Gynecol 2015; 213:703.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Maternal-Fetal Medicine (SMFM). Electronic address:
           <span class="__cf_email__" data-cfemail="8cfcf9eeffccffe1eae1a2e3feeb">
            [email protected]
           </span>
           , McIntosh J, Feltovich H, et al. The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention. Am J Obstet Gynecol 2016; 215:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly A, Thorp JM Jr. Urinary tract infections in pregnancy. Urol Clin North Am 1999; 26:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uncu Y, Uncu G, Esmer A, Bilgel N. Should asymptomatic bacteriuria be screened in pregnancy? Clin Exp Obstet Gynecol 2002; 29:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smaill F, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev 2007; :CD000490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medley N, Poljak B, Mammarella S, Alfirevic Z. Clinical guidelines for prevention and management of preterm birth: a systematic review. BJOG 2018; 125:1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Multicenter randomized, controlled trial of a preterm birth prevention program. Collaborative Group on Preterm Birth Prevention. Am J Obstet Gynecol 1993; 169:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urquhart C, Currell R, Harlow F, Callow L. Home uterine monitoring for detecting preterm labour. Cochrane Database Syst Rev 2017; 2:CD006172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234. Obstet Gynecol 2021; 138:e65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitworth M, Quenby S. Prophylactic oral betamimetics for preventing preterm labour in singleton pregnancies. Cochrane Database Syst Rev 2008; :CD006395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khanprakob T, Laopaiboon M, Lumbiganon P, Sangkomkamhang US. Cyclo-oxygenase (COX) inhibitors for preventing preterm labour. Cochrane Database Syst Rev 2012; 10:CD007748.
          </a>
         </li>
         <li class="breakAll">
          American College of Obstetricians and Gynecologists' Practice Advisory: Low-Dose Aspirin Use for the Prevention of Preeclampsia and Related Morbidity and Mortality. December 2021. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/12/low-dose-aspirin-use-for-the-prevention-of-preeclampsia-and-related-morbidity-and-mortality (Accessed on December 21, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman MK, Goudar SS, Kodkany BS, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. Lancet 2020; 395:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landman AJEMC, de Boer MA, Visser L, et al. Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm labour (the APRIL study): A multicentre, randomised, double-blinded, placebo-controlled trial. PLoS Med 2022; 19:e1003892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodgetts Morton V, Stock SJ. Low-dose aspirin for the prevention of preterm birth: More questions than answers. PLoS Med 2022; 19:e1003908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldenberg RL, Cliver SP, Bronstein J, et al. Bed rest in pregnancy. Obstet Gynecol 1994; 84:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sciscione AC. Maternal activity restriction and the prevention of preterm birth. Am J Obstet Gynecol 2010; 202:232.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sosa CG, Althabe F, Belizán JM, Bergel E. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev 2015; :CD003581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grobman WA, Gilbert SA, Iams JD, et al. Activity restriction among women with a short cervix. Obstet Gynecol 2013; 121:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox NS, Jean-Pierre C, Predanic M, Chasen ST. Does hospitalization prevent preterm delivery in the patient with a short cervix? Am J Perinatol 2007; 24:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yost NP, Bloom SL, McIntire DD, Leveno KJ. Hospitalization for women with arrested preterm labor: a randomized trial. Obstet Gynecol 2005; 106:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zemet R, Schiff E, Manovitch Z, et al. Quantitative assessment of physical activity in pregnant women with sonographic short cervix and the risk for preterm delivery: A prospective pilot study. PLoS One 2018; 13:e0198949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 2000; 182:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. Cochrane Database Syst Rev 2010; :CD000110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdul Sultan A, West J, Tata LJ, et al. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. BMJ 2013; 347:f6099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Convertino VA, Bloomfield SA, Greenleaf JE. An overview of the issues: physiological effects of bed rest and restricted physical activity. Med Sci Sports Exerc 1997; 29:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moscrop A. Can sex during pregnancy cause a miscarriage? A concise history of not knowing. Br J Gen Pract 2012; 62:e308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ribeiro MC, de Tubino Scanavino M, do Amaral MLS, et al. Beliefs About Sexual Activity During Pregnancy: A Systematic Review of the Literature. J Sex Marital Ther 2017; 43:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ 2004; 329:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001; 345:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subtil D, Brabant G, Tilloy E, et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet 2018; 392:2171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin DH, Eschenbach DA, Cotch MF, et al. Double-Blind Placebo-Controlled Treatment Trial of Chlamydia trachomatis Endocervical Infections in Pregnant Women. Infect Dis Obstet Gynecol 1997; 5:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leitich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol 2003; 188:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000; 342:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2000; :CD000262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haahr T, Ersbøll AS, Karlsen MA, et al. Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery - a clinical recommendation. Acta Obstet Gynecol Scand 2016; 95:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eschenbach DA, Nugent RP, Rao AV, et al. A randomized placebo-controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery. The Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1991; 164:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raynes-Greenow CH, Roberts CL, Bell JC, et al. Antibiotics for ureaplasma in the vagina in pregnancy. Cochrane Database Syst Rev 2004; :CD003767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klebanoff MA, Regan JA, Rao AV, et al. Outcome of the Vaginal Infections and Prematurity Study: results of a clinical trial of erythromycin among pregnant women colonized with group B streptococci. Am J Obstet Gynecol 1995; 172:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kigozi GG, Brahmbhatt H, Wabwire-Mangen F, et al. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2003; 189:1398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gülmezoglu AM, Azhar M. Interventions for trichomoniasis in pregnancy. Cochrane Database Syst Rev 2011; :CD000220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stringer E, Read JS, Hoffman I, et al. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. S Afr Med J 2010; 100:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simcox R, Sin WT, Seed PT, et al. Prophylactic antibiotics for the prevention of preterm birth in women at risk: a meta-analysis. Aust N Z J Obstet Gynaecol 2007; 47:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thinkhamrop J, Hofmeyr GJ, Adetoro O, et al. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. Cochrane Database Syst Rev 2015; 1:CD002250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellad MB, Hoffman MK, Mallapur AA, et al. Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial. BJOG 2018; 125:1601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garite TJ, Manuck TA. Should case management be considered a component of obstetrical interventions for pregnancies at risk of preterm birth? Am J Obstet Gynecol 2023; 228:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merchant AT, Gupta RD, Akonde M, et al. Association of Chlorhexidine Use and Scaling and Root Planing With Birth Outcomes in Pregnant Individuals With Periodontitis: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2247632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michalowicz BS, Gustafsson A, Thumbigere-Math V, Buhlin K. The effects of periodontal treatment on pregnancy outcomes. J Clin Periodontol 2013; 40 Suppl 14:S195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer MS. Isocaloric balanced protein supplementation in pregnancy. Cochrane Database Syst Rev 2000; :CD000118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ota E, Tobe-Gai R, Mori R, Farrar D. Antenatal dietary advice and supplementation to increase energy and protein intake. Cochrane Database Syst Rev 2012; :CD000032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vahratian A, Siega-Riz AM, Savitz DA, Thorp JM Jr. Multivitamin use and the risk of preterm birth. Am J Epidemiol 2004; 160:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fawzi WW, Msamanga GI, Urassa W, et al. Vitamins and perinatal outcomes among HIV-negative women in Tanzania. N Engl J Med 2007; 356:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinnato JA 2nd, Freire S, Pinto e Silva JL, et al. Antioxidant supplementation and premature rupture of the membranes: a planned secondary analysis. Am J Obstet Gynecol 2008; 199:433.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rumbold A, Ota E, Nagata C, et al. Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev 2015; :CD004072.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rumbold A, Ota E, Hori H, et al. Vitamin E supplementation in pregnancy. Cochrane Database Syst Rev 2015; :CD004069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saccone G, Berghella V. Folic acid supplementation in pregnancy to prevent preterm birth: a systematic review and meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2016; 199:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-López FR, Pasupuleti V, Mezones-Holguin E, et al. Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2015; 103:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Catov JM, Bodnar LM, Ness RB, et al. Association of periconceptional multivitamin use and risk of preterm or small-for-gestational-age births. Am J Epidemiol 2007; 166:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middleton P, Gomersall JC, Gould JF, et al. Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev 2018; 11:CD003402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ACOG Committee Opinion No. 733: Employment Considerations During Pregnancy and the Postpartum Period. Obstet Gynecol 2018; 131:e115. Reaffirmed 2023.
          </a>
         </li>
         <li class="breakAll">
          https://www.eeoc.gov/eeoc/publications/pregnant_workers.cfm (Accessed on March 03, 2020).
         </li>
         <li class="breakAll">
          https://www.hse.gov.uk/mothers/law.htm (Accessed on March 03, 2020).
         </li>
         <li class="breakAll">
          https://handbookgermany.de/en/live/pregnancy.html (Accessed on March 03, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkowitz GS, Papiernik E. Working conditions, maternity legislation, and preterm birth. Semin Perinatol 1995; 19:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodnett ED, Fredericks S. Support during pregnancy for women at increased risk of low birthweight babies. Cochrane Database Syst Rev 2003; :CD000198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khianman B, Pattanittum P, Thinkhamrop J, Lumbiganon P. Relaxation therapy for preventing and treating preterm labour. Cochrane Database Syst Rev 2012; :CD007426.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 140781 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.cdc.gov/mmwr/volumes/65/wr/mm6532a4.htm?s_cid=mm6532a4_e" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : http://www.cdc.gov/mmwr/volumes/65/wr/mm6532a4.htm?s_cid=mm6532a4_e.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22596383" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16622143" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Birth spacing and risk of adverse perinatal outcomes: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11101017" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Unintended pregnancy and preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26220110" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The impact of postpartum contraception on reducing preterm birth: findings from California.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27133011" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The role of routine cervical length screening in selected high- and low-risk women for preterm birth prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10584618" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Urinary tract infections in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12635746" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Should asymptomatic bacteriuria be screened in pregnancy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17443502" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Antibiotics for asymptomatic bacteriuria in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29460323" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical guidelines for prevention and management of preterm birth: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8362947" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Multicenter randomized, controlled trial of a preterm birth prevention program. Collaborative Group on Preterm Birth Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28205207" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Home uterine monitoring for detecting preterm labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34293771" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18254101" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prophylactic oral betamimetics for preventing preterm labour in singleton pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23076936" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cyclo-oxygenase (COX) inhibitors for preventing preterm labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23076936" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cyclo-oxygenase (COX) inhibitors for preventing preterm labour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31982074" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35104279" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm labour (the APRIL study): A multicentre, randomised, double-blinded, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35104288" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Low-dose aspirin for the prevention of preterm birth: More questions than answers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8008308" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Bed rest in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19766979" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Maternal activity restriction and the prevention of preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25821121" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Bed rest in singleton pregnancies for preventing preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23812450" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Activity restriction among women with a short cervix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17195150" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Does hospitalization prevent preterm delivery in the patient with a short cervix?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994611" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hospitalization for women with arrested preterm labor: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29889906" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Quantitative assessment of physical activity in pregnant women with sonographic short cervix and the risk for preterm delivery: A prospective pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10819836" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20614420" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hospitalisation and bed rest for multiple pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24201164" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9044221" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : An overview of the issues: physiological effects of bed rest and restricted physical activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22520919" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Can sex during pregnancy cause a miscarriage? A concise history of not knowing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28287929" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Beliefs About Sexual Activity During Pregnancy: A Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15294856" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11519502" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30322724" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18476128" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Double-Blind Placebo-Controlled Treatment Trial of Chlamydia trachomatis Endocervical Infections in Pregnant Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12634652" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10684911" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796189" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Interventions for treating bacterial vaginosis in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27258798" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery - a clinical recommendation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2003533" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A randomized placebo-controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery. The Vaginal Infections and Prematurity Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14974036" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antibiotics for ureaplasma in the vagina in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7755068" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Outcome of the Vaginal Infections and Prematurity Study: results of a clinical trial of erythromycin among pregnant women colonized with group B streptococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634576" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21563127" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Interventions for trichomoniasis in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20429491" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17877593" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prophylactic antibiotics for the prevention of preterm birth in women at risk: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25621770" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29790266" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36130634" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Should case management be considered a component of obstetrical interventions for pregnancies at risk of preterm birth?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36534397" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Association of Chlorhexidine Use and Scaling and Root Planing With Birth Outcomes in Pregnant Individuals With Periodontitis: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23627329" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : The effects of periodontal treatment on pregnancy outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796141" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Isocaloric balanced protein supplementation in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22972038" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Antenatal dietary advice and supplementation to increase energy and protein intake.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15496541" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Multivitamin use and the risk of preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17409323" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Vitamins and perinatal outcomes among HIV-negative women in Tanzania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18928997" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Antioxidant supplementation and premature rupture of the membranes: a planned secondary analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26415762" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Vitamin C supplementation in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26343254" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Vitamin E supplementation in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26901401" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Folic acid supplementation in pregnancy to prevent preterm birth: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25813278" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes: a systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17496313" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Association of periconceptional multivitamin use and risk of preterm or small-for-gestational-age births.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30480773" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Omega-3 fatty acid addition during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29578986" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : ACOG Committee Opinion No. 733: Employment Considerations During Pregnancy and the Postpartum Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29578986" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : ACOG Committee Opinion No. 733: Employment Considerations During Pregnancy and the Postpartum Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29578986" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : ACOG Committee Opinion No. 733: Employment Considerations During Pregnancy and the Postpartum Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29578986" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : ACOG Committee Opinion No. 733: Employment Considerations During Pregnancy and the Postpartum Period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8560292" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Working conditions, maternity legislation, and preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12917888" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Support during pregnancy for women at increased risk of low birthweight babies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22895959" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Relaxation therapy for preventing and treating preterm labour.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
